Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | SCN4A | P35499 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4103711 | 0.94 | CYP1A2 (0.57) | CYP1A2CYP19A1CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL28688499 | 0.85 | CYP1A2 (0.56) | CYP1A2CYP19A1CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL9768763 | 0.82 | NOTUM (0.77) | CYP1A2CYP19A1CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL2090452 | 0.80 | CYP1A2 (0.57) | CYP1A2CYP19A1CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL28329742 | 0.78 | CYP1A2 (0.64) | CYP1A2CYP19A1CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL30238219 | 0.78 | CYP1A2 (0.64) | CYP1A2CYP19A1CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL2556889 | 0.77 | RAB9A (0.65) | CYP1A2CYP19A1CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL14129960 | 0.77 | CYP19A1 (1.00) | CYP1A2CYP19A1CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL4090826 | 0.76 | CYP1A2 (0.53) | CYP1A2CYP19A1CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL22827782 | 0.74 | CYP19A1 (0.94) | CYP1A2CYP19A1CYP2C9CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | claimed |
| CN-104379578-B | Carbamate compounds and its preparation and application | 阿比德治疗公司 | 2017-06-09 | — | — | CN | claimed |
| US-20250257056-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-08-14 | — | — | US | disclosed |
| US-12319672-B2 | Alpha-D-galactopyranoside derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-06-03 | — | — | US | disclosed |
| CN-115716822-B | Application of benzimidazolyl isoxazoles in preparation of medicines related to multiple myeloma | 徐州医科大学 | 2025-05-16 | — | — | CN | disclosed |
| CN-115716822-A | Application of benzimidazolyl isoxazole compound in preparation of medicines related to multiple myeloma | 徐州医科大学 | 2023-02-28 | — | — | CN | disclosed |
| CN-110483430-B | Preparation method of isoxazole derivative | 上海应用技术大学 | 2023-02-10 | — | — | CN | disclosed |
| US-20220281855-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-08 | — | — | US | disclosed |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | IPS HEART | 2021-02-25 | — | — | US | disclosed |
| CN-110483430-A | A kind of preparation method of Isoxazole derivative | SHANGHAI INST TECH | 2019-11-22 | — | — | CN | disclosed |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | EXOSC9, EXOSC5, EXOSC4 | CYP1A2 4772/4885CYP19A1 4799/4885CYP2C9 4796/4885 |
| US-20250257056-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | LGALS1, LGALS3, LGALS2 | CYP1A2 1221/4885CYP19A1 1383/4885CYP2C9 3082/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | CYP1A2 420/4885CYP19A1 3013/4885CYP2C9 2206/4885 |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | EXOSC5, UTRN, EXOSC4 | CYP1A2 4772/4885CYP19A1 4809/4885CYP2C9 4834/4885 |
| US-20220281855-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | LGALS1, LGALS3, LGALS2 | CYP1A2 720/4885CYP19A1 2177/4885CYP2C9 1161/4885 |
| US-12319672-B2 | Alpha-D-galactopyranoside derivatives | LGALS1, LGALS3, LGALS2 | CYP1A2 720/4885CYP19A1 2177/4885CYP2C9 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.